Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 2
1995 1
1996 2
1997 2
1998 2
1999 2
2000 2
2001 1
2002 5
2003 2
2004 4
2005 2
2006 3
2007 2
2008 2
2009 4
2010 3
2012 1
2013 4
2014 4
2015 4
2016 2
2017 2
2018 5
2019 2
2020 4
2021 8
2022 6
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Fluoropyrimidine-induced cardiotoxicity.
Depetris I, Marino D, Bonzano A, Cagnazzo C, Filippi R, Aglietta M, Leone F. Depetris I, et al. Crit Rev Oncol Hematol. 2018 Apr;124:1-10. doi: 10.1016/j.critrevonc.2018.02.002. Epub 2018 Feb 7. Crit Rev Oncol Hematol. 2018. PMID: 29548480 Review.
This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endothelium and cardiomyocytes damage, toxic metabolites, dihydropyrimidine dehydrogenase deficiency); risk and predictive fa …
This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endoth …
Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
Etienne-Grimaldi MC, Pallet N, Boige V, Ciccolini J, Chouchana L, Barin-Le Guellec C, Zaanan A, Narjoz C, Taieb J, Thomas F, Loriot MA; Francophone Network of Pharmacogenetics (RNPGx) and the French Clinical Oncopharmacology Group (GPCO)-UNICANCER. Etienne-Grimaldi MC, et al. Eur J Cancer. 2023 Mar;181:3-17. doi: 10.1016/j.ejca.2022.11.028. Epub 2022 Dec 9. Eur J Cancer. 2023. PMID: 36621118 Review.
The rate-limiting step of fluoropyrimidine catabolism is dihydropyrimidine dehydrogenase (DPD), and deficiency in DPD activity can result in severe and even fatal toxicity. In this review, we survey the evidence-based pharmacogenetics and therapeutic recommen …
The rate-limiting step of fluoropyrimidine catabolism is dihydropyrimidine dehydrogenase (DPD), and deficiency in DPD a …
Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.
White C, Scott RJ, Paul C, Ziolkowski A, Mossman D, Fox SB, Michael M, Ackland S. White C, et al. Clin Pharmacol Ther. 2022 Oct;112(4):791-802. doi: 10.1002/cpt.2667. Epub 2022 Jun 12. Clin Pharmacol Ther. 2022. PMID: 35607723 Review.
Fluoropyrimidines (FP; 5-fluorouracil, capecitabine, and tegafur) are a commonly prescribed class of antimetabolite chemotherapies, used for various solid organ malignancies in over 2 million patients globally per annum. Dihydropyrimidine dehydrogenase (DPD), encode …
Fluoropyrimidines (FP; 5-fluorouracil, capecitabine, and tegafur) are a commonly prescribed class of antimetabolite chemotherapies, used for …
DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand?
Lešnjaković L, Ganoci L, Bilić I, Šimičević L, Mucalo I, Pleština S, Božina N. Lešnjaković L, et al. Pharmacogenomics. 2023 Jan;24(2):93-106. doi: 10.2217/pgs-2022-0135. Epub 2023 Jan 13. Pharmacogenomics. 2023. PMID: 36636997 Review.
While European regulatory agencies and clinical societies recommend pre-treatment DPD deficiency screening for patients starting treatment with FPs, this is not the case with American ones. ...New evidence on additional common DPYD polymorphisms, as well as identification …
While European regulatory agencies and clinical societies recommend pre-treatment DPD deficiency screening for patients starting trea …
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.
Wörmann B, Bokemeyer C, Burmeister T, Köhne CH, Schwab M, Arnold D, Blohmer JU, Borner M, Brucker S, Cascorbi I, Decker T, de Wit M, Dietz A, Einsele H, Eisterer W, Folprecht G, Hilbe W, Hoffmann J, Knauf W, Kunzmann V, Largiadèr CR, Lorenzen S, Lüftner D, Moehler M, Nöthen MM, Pox C, Reinacher-Schick A, Scharl A, Schlegelberger B, Seufferlein T, Sinn M, Stroth M, Tamm I, Trümper L, Wilhelm M, Wöll E, Hofheinz RD. Wörmann B, et al. Oncol Res Treat. 2020;43(11):628-636. doi: 10.1159/000510258. Epub 2020 Oct 23. Oncol Res Treat. 2020. PMID: 33099551 Free article. Review.
SUMMARY: Among other risk factors associated with increased toxicity, a genetic deficiency in dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for the metabolism of FU, is well known. ...
SUMMARY: Among other risk factors associated with increased toxicity, a genetic deficiency in dihydropyrimidine dehydrogena …
DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.
Paulsen NH, Vojdeman F, Andersen SE, Bergmann TK, Ewertz M, Plomgaard P, Hansen MR, Esbech PS, Pfeiffer P, Qvortrup C, Damkier P. Paulsen NH, et al. Basic Clin Pharmacol Toxicol. 2022 Nov;131(5):325-346. doi: 10.1111/bcpt.13782. Epub 2022 Sep 8. Basic Clin Pharmacol Toxicol. 2022. PMID: 35997509 Free PMC article. Review.
BACKGROUND: In clinical oncology, systemic 5-fluorouracil (5-FU) and its oral pro-drugs are used to treat a broad group of solid tumours. Patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency are at elevated risk of toxicity if treated with st …
BACKGROUND: In clinical oncology, systemic 5-fluorouracil (5-FU) and its oral pro-drugs are used to treat a broad group of solid tumours. Pa …
Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency.
Van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, Van Lenthe H, De Abreu RA, Smeitink JA, Kayserili H, Apak MY, Christensen E, Holopainen I, Pulkki K, Riva D, Botteon G, Holme E, Tulinius M, Kleijer WJ, Beemer FA, Duran M, Niezen-Koning KE, Smit GP, Jakobs C, Smit LM, Van Gennip AH, et al. Van Kuilenburg AB, et al. Hum Genet. 1999 Jan;104(1):1-9. doi: 10.1007/pl00008711. Hum Genet. 1999. PMID: 10071185 Review.
Dihydropyrimidine dehydrogenase (DPD) deficiency is an autosomal recessive disease characterised by thymine-uraciluria in homozygous deficient patients and has been associated with a variable clinical phenotype. In order to understand the genetic and phenotyp …
Dihydropyrimidine dehydrogenase (DPD) deficiency is an autosomal recessive disease characterised by thymine-uraciluria …
The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.
Gardiner SJ, Begg EJ, Robinson BA. Gardiner SJ, et al. Adverse Drug React Toxicol Rev. 2002;21(1-2):1-16. doi: 10.1007/BF03256180. Adverse Drug React Toxicol Rev. 2002. PMID: 12140902 Review.
The variable pharmacology is largely due to inherited differences in expression of the metabolising enzyme dihydropyrimidine dehydrogenase (DPD). This converts fluorouracil to inactive metabolites (catabolic pathway) and ultimately dictates the amount of fluorouraci …
The variable pharmacology is largely due to inherited differences in expression of the metabolising enzyme dihydropyrimidine dehyd …
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
van Kuilenburg AB. van Kuilenburg AB. Eur J Cancer. 2004 May;40(7):939-50. doi: 10.1016/j.ejca.2003.12.004. Eur J Cancer. 2004. PMID: 15093568 Review.
The identification of genetic factors associated with either responsiveness or resistance to 5-fluorouracil (5-FU) chemotherapy, as well as genetic factors predisposing patients to the development of severe 5-FU-associated toxicity, is increasingly being recognised as an importan …
The identification of genetic factors associated with either responsiveness or resistance to 5-fluorouracil (5-FU) chemotherapy, as well as …
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Lee A, Ezzeldin H, Fourie J, Diasio R. Lee A, et al. Clin Adv Hematol Oncol. 2004 Aug;2(8):527-32. Clin Adv Hematol Oncol. 2004. PMID: 16163233 Review.
Through the use of pharmacogenetic studies, interindividual variability in response (efficacy and toxicity) to 5-fluorouracil (5-FU) chemotherapy has been linked to the rate-limiting enzyme in the drug's catabolic pathway, known as dihydropyrimidine dehydrogenase (D …
Through the use of pharmacogenetic studies, interindividual variability in response (efficacy and toxicity) to 5-fluorouracil (5-FU) chemoth …
81 results